Search by Abstract Number Results

Abstract Number: 2728 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Upadacitinib in a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2/3 Clinical Study of Patients with Active Ankylosing Spondylitis
Désirée van der Heijde¹, In-Ho Song ², Aileen Pangan ³, Atul Deodhar ⁴, Filip Van den Bosch ⁵, Walter P. Maksymowych ⁶, Tae-Hwan Kim ⁷, Mitsumasa Kishimoto ⁸, Andrea Everding ⁹, Yunxia Sui ¹⁰, Xin Wang ¹⁰, Alvina D. Chu ¹⁰ and Joachim Sieper ¹¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ³AbbVie Inc., North Chicago, ⁴Oregon Health & Science University, Portland, OR, ⁵Ghent University Hospital, Ghent, Belgium, ⁶University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada, ⁷Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁸Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan, ⁹HRF Hamburger Rheuma Forschungszentrum, Hamburg, Germany, ¹⁰AbbVie Inc., Chicago, ¹¹Charité Universitätsmedizin Berlin, Germany, Berlin, Germany
Background/Purpose: Patients (pts) with ankylosing spondylitis (AS) who have an inadequate response/contraindication to NSAIDs have limited treatment options other than biologics. The Janus kinase (JAK)…
Abstract Number: 2728 • 2018 ACR/ARHP Annual Meeting
Validation of the Draft Classification Criteria of Granulomatosis with Polyangiitis (GPA) Amongst Indian Patients with ANCA Associated Vasculitis
Aman Sharma¹, Adarsh MB², GSRSNK Naidu³, Manish Rathi⁴, Kusum Sharma⁵, Varun Dhir⁶, Ritambhra Nada⁷, Ranjana Minz⁸ and Sanjay Jain⁹, ¹Clinical Immunology and Rheumatology Services, Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India, Chandigarh, India, ²Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India, Chandigarh, India, ³PGIMER, cHANDIGARH, India, ⁴Department of Nephrology,, Postgraduate Institute of Medical Education and Research, Chandigarh, India, ⁵Department of Medical Microbiology,, PGIMER,, Chandigarh, India, ⁶Internal Medicine (Rheumatology Unit), Postgraduate Institute of Medical Education and Research, Chandigarh, India, Chandigarh, India, ⁷Postgraduate Institute of Medical Education and Research, Chandigarh, India, ⁸Department of Immunopathology,, PGIMER,, Chandigarh, India, ⁹Postgraduate Institute of Medical Education and Research, Chandigarh, India, CHANDIGARH, India
Background/Purpose: A draft classification criteria of GPA was proposed at ACR meeting in San Diego in 2017. The present criteria is a modification of ACR/EULAR…
Abstract Number: 2728 • 2017 ACR/ARHP Annual Meeting
Serum Levels of Interleukin-36 Receptor Antagonist in Behçet’s Patients
Pelin Ünsal¹, Pamir Cerci², Şükrü Alper Açıkgöz², Göksal Keskin² and Ümit Ölmez², ¹Ankara University School of Medicine, Ankara, Turkey, ²Immunology and Allergy, Ankara University School of Medicine, Ankara, Turkey
Background/Purpose: Behcet's disease (BD) is a systemic vasculitis disorder of unknown etiology with recurrent exacerbations and remissions. The etiopathogenesis of the disease is still unclear.…
Abstract Number: 2728 • 2016 ACR/ARHP Annual Meeting
Discontinuation of Biologic Therapy in Patients with Ankylosing Spondylitis—Data from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Philip J Mease¹, Désirée van der Heijde², Chitra Karki³, Mei Liu³, Renganayaki Pandurengan³, Yujin Park⁴ and Jeffrey D. Greenberg^3,5, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Corrona, LLC, Southborough, MA, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵New York University School of Medicine, New York, NY
Background/Purpose: Clinical trials have demonstrated the efficacy of biologic therapy in improving the clinical and patient-reported outcomes in patients with ankylosing spondylitis (AS); however, there…
Abstract Number: 2728 • 2015 ACR/ARHP Annual Meeting
Baseline Characteristics and Changes in Disease Activity at 12 Months in Patients Treated with Abatacept Versus Other Biologic Disease-Modifying Antirheumatic Drugs in Clinical Practice Setting
E Alemao¹, S Joo², M Frits³, C Iannaccone³, N Shadick³ and Michael Weinblatt³, ¹Bristol-Myers Squibb, Princeton, NJ, ²Bristol-Myers Squibb, Hopewell, NJ, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: Biologic (b)DMARDs have advanced the standard of care in RA, reducing unmet needs and increasing remission rates. Abatacept (ABA) is approved for the management…
Abstract Number: 2728 • 2014 ACR/ARHP Annual Meeting
Reduction of MAIT Cell Frequency Associated with Reduced Cell Proliferation and Enhanced Cell Death in Systemic Lupus Erythematosus
Asako Chiba¹, Naoto Tamura², Eri Hayashi², Ran Matsudaira³, Yoshinari Takasaki⁴ and Sachiko Miyake¹, ¹Immunology, Juntendo University School of Medicine, Tokyo, Japan, ²Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ³Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ⁴Department of Rheumatology, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Mucosal-associated invariant T (MAIT) cells are innate-like lymphocytes which are restricted by the MHC-related molecule-1 (MR1) and express a semi-invariant TCRα chain: Vα7.2-Jα33 in…
Abstract Number: 2728 • 2013 ACR/ARHP Annual Meeting
The Small Ubiquitin Related Modifier-1 (SUMO-1) Regulates Osteoclast Differentiation In Vitro and In Vivo.
Svetlana Frank¹, Daniel Umlauf², Olli A. Jänne³ and Thomas Pap⁴, ¹Institute of Experimental Musculoskeletal Medicine, University Hospital Münster, Muenster, Germany, ²Institute of Experimental Musculoskeletal Medicine, University Hospital Muenster, Muenster, Germany, ³Univ Helsinki, Inst Biomed Physiol, Biomedicum, Helsinki, Finland, ⁴Institute of Experimental Muskuloskeletal Medicine, University Hospital Münster, Münster, Germany
Background/Purpose: Posttranslational modification of proteins by SUMO has been shown for a number of target molecules including transcription factors and is involved in a variety…

Search Again »

Didn't find what you were looking for? Try the Advanced Search »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].